Why the study?
Does monitoring drug plasma levels of dabigatran improve safety?
Does monitoring drug plasma levels of dabigatran improve safety?
An investigation suggests that recommendations for dabigatran may be flawed because the manufacturer withheld evidence that monitoring plasma levels could improve safety.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
David D. Cohen (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: